GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetics Generation Advancement Corp (ROCO:4160) » Definitions » Cash Ratio

Genetics Generation Advancement (ROCO:4160) Cash Ratio : 2.46 (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Genetics Generation Advancement Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Genetics Generation Advancement's Cash Ratio for the quarter that ended in Dec. 2024 was 2.46.

Genetics Generation Advancement has a Cash Ratio of 2.46. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Genetics Generation Advancement's Cash Ratio or its related term are showing as below:

ROCO:4160' s Cash Ratio Range Over the Past 10 Years
Min: 1.93   Med: 2.45   Max: 3.15
Current: 2.46

During the past 13 years, Genetics Generation Advancement's highest Cash Ratio was 3.15. The lowest was 1.93. And the median was 2.45.

ROCO:4160's Cash Ratio is ranked better than
73.97% of 219 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.1 vs ROCO:4160: 2.46

Genetics Generation Advancement Cash Ratio Historical Data

The historical data trend for Genetics Generation Advancement's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetics Generation Advancement Cash Ratio Chart

Genetics Generation Advancement Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.17 1.93 2.44 2.04 2.46

Genetics Generation Advancement Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.04 2.46 2.73 2.37 2.46

Competitive Comparison of Genetics Generation Advancement's Cash Ratio

For the Diagnostics & Research subindustry, Genetics Generation Advancement's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetics Generation Advancement's Cash Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Genetics Generation Advancement's Cash Ratio falls into.


;
;

Genetics Generation Advancement Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Genetics Generation Advancement's Cash Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash Ratio (A: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=414.482/168.431
=2.46

Genetics Generation Advancement's Cash Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash Ratio (Q: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=414.482/168.431
=2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetics Generation Advancement  (ROCO:4160) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Genetics Generation Advancement Cash Ratio Related Terms

Thank you for viewing the detailed overview of Genetics Generation Advancement's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetics Generation Advancement Business Description

Traded in Other Exchanges
N/A
Address
No. 28, Lane 36, Xinhu 1st Road, 6th Floor, Neihu District, Taipei, TWN, 11494
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.

Genetics Generation Advancement Headlines

No Headlines